Ann Gurell

Title: Ann Gurell: Innovator in Neurotoxin Formulations

Introduction

Ann Gurell is a notable inventor based in Stockholm, Sweden. She has made significant contributions to the field of neurotoxin formulations, particularly focusing on creating stable liquid compositions that are free of animal proteins. Her innovative work has implications for therapeutic and aesthetic applications.

Latest Patents

Ann Gurell holds a patent for a liquid neurotoxin formulation stabilized with tryptophan or tyrosine. This invention relates to stable liquid neurotoxin formulations that include a surfactant, an amino acid selected from tryptophan and tyrosine, and a buffer comprising sodium, chloride, and phosphate ions. The formulations have a pH between 5.5 and 8 and are stable for two months. These compositions are designed for therapeutic use, particularly for administration to patients to achieve desired therapeutic or aesthetic effects. The invention also highlights the use of tryptophan and tyrosine to protect proteinaceous neurotoxins from degradation in liquid compositions that are free of animal-derived proteins.

Career Highlights

Throughout her career, Ann Gurell has worked with prominent companies in the pharmaceutical and biotechnology sectors. Notably, she has been associated with Ipsen Biopharm Limited and Galderma Holding SA. Her work in these organizations has allowed her to contribute to advancements in medical formulations and therapies.

Collaborations

Ann has collaborated with several professionals in her field, including Anders Jarstad and Anna Friis. These collaborations have fostered innovation and development in neurotoxin formulations.

Conclusion

Ann Gurell's contributions to the field of neurotoxin formulations demonstrate her commitment to advancing therapeutic solutions. Her innovative patent and collaborations highlight her role as a key figure in this area of research.